Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRAINSTORM CELL THERAPEUTICS INC.BCLI · Entity 7869 | Director | February 26, 2026 | May 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRAINSTORM CELL THERAPEUTICS INC.
Report date February 26, 2026 · Filed May 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.70 · Expires 2036-02-26 | Direct | 225,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 225,000 · Balance 225,000 F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan.
F2: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2026 Filed May 20, 2026 22:05 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (Right to Buy) · Derivative | 225,000 | $0.70 Strike: $0.70 | $157,500.00 |
DisclosureSEC source: 0001104659-26-064656 · tm267728-4_4seq1.xml · derivative · entry 1 HARTOUNIAN HARTOUN · CIK 0001214476 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2036-02-26 F1 · security: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F1 · price: Represents options to purchase common stock, granted under the Issuer's 2014 Stock Incentive Plan. F2 · derivative.exercise_date: The Stock Options shall vest as to (i) 50% of the award on the date of grant and (ii) the remaining 50% of the award shall vest on the six-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. Read SEC document |
| January 01, 2025 Filed Jan 3, 2025 22:31 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000888 · tm251864-3_4seq1.xml · nonDerivative · entry 1 HARTOUNIAN HARTOUN · CIK 0001214476 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 F1 · shares: Represents shares of restricted stock awarded under the Issuer's 2014 Stock Incentive Plan. The shares of restricted stock shall vest as to (i) 50% of the award on the six-month anniversary of the date of grant and (ii) the remaining 50% of the award shall vest on the eighteenth-month anniversary of the date of grant, provided that the Reporting Person remains employed by the Issuer through each applicable vesting date. F2 · balance_after: Reflects the Issuer's 1-for-15 reverse stock split effected market open on October 1, 2024. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 01:04 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001104659-24-074873 · tm2418256-2_4seq1.xml · derivative · entry 2 HARTOUNIAN HARTOUN · CIK 0001214476 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2034-06-24 F2 · derivative.exercise_date: The option (the "Option"), awarded under the Plan, shall vest and become exercisable as to 25% of the underlying shares on June 24, 2025, and the remaining shares underlying the Option shall vest and become exercisable in equal quarterly installments thereafter, until fully vested and exercisable on the fourth anniversary of the grant date, provided that the Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 01:04 UTC | BRAINSTORM CELL THERAPEUTICS INC. BCLI · Entity 7869 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-074873 · tm2418256-2_4seq1.xml · nonDerivative · entry 1 HARTOUNIAN HARTOUN · CIK 0001214476 · EVP, Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 F1 · shares: Represents shares of restricted stock units ("RSUs") awarded under the Issuer's 2014 Stock Incentive Plan (the "Plan"). The RSUs will vest in full on June 24, 2025, provided that the Reporting Person remains employed by Issuer from the date of grant through the vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.